Purpose: Fatigue is a distressing symptom occurring in more than 60% of patients with cancer. The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue, despite a limited evidence base. We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non-small-cell lung cancer (NSCLC).
Patients And Methods: Adults with advanced NSCLC and performance status of 0 to 2, who were not treated with chemotherapy or radiotherapy within the last 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo. The primary outcome was change in Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue score from baseline to 28 days, adjusted for baseline fatigue and performance status. Secondary outcomes included safety and patient-reported measures of depression, daytime sleepiness, and quality of life.
Results: A total of 208 patients were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionnaires at both baseline and day 28 and were included in the modified intention-to-treat analysis. FACIT-Fatigue scores improved from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95% CI, 2.54 to 7.65), but there was no difference between treatments (0.20; 95% CI, -3.56 to 3.97). There was also no difference between treatments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that the intervention was not helpful.
Conclusion: Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting. Its use was associated with a clinically significant placebo effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2013.54.4346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First Episode Psychosis in a Teen with Narcolepsy and Cataplexy.
Psychopharmacol Bull
January 2025
Abhishek Reddy, MD, Assistant Professor, Child and Adolescent Psychiatry, Sleep Medicine, Department of Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.
Article Synopsis
- Narcolepsy with cataplexy (NT1) is a rare sleep disorder that can be linked to early-onset psychosis, particularly in kids and teens.
- After excluding other medical issues, an adolescent girl with NT1 was initially diagnosed with a brief psychotic episode and treated with Risperidone.
- Her symptoms improved significantly after switching to Chlorpromazine, marking one of the first successful uses of this drug for managing first-episode psychosis in a patient with NT1.
The observation of seasonal variation of fatigue in multiple sclerosis depends on the measurement instrument.
Mult Scler Relat Disord
December 2024
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA. Electronic address:
Article Synopsis
- The study investigates how seasonal temperature changes affect fatigue levels in multiple sclerosis (MS) patients, a common symptom of the disease.
- Fatigue was assessed using two different measurement tools: the Modified Fatigue Impact Scale (MFIS) and the Neuro-QoL fatigue score, with the results showing that MFIS scores were influenced by season and location, while Neuro-QoL scores were not.
- The findings suggest that the effect of temperature on MS-related fatigue varies based on the specific measurement tool used.
Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data.
Sleep Adv
December 2024
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Study Objectives: To estimate the prevalence and incidence and evaluate the treatment patterns of patients diagnosed with narcolepsy in specialist care in Sweden.
Methods: This non-interventional retrospective longitudinal study used Swedish register data from 2010 to 2020 and included patients diagnosed with narcolepsy (either type 1 or type 2), recorded in specialist outpatient and inpatient care from January 2015 to December 2019. All patients received an index date corresponding to the date of the first narcolepsy diagnosis.
Armodafinil as Monotherapy in Treating Narcolepsy with Cataplexy.
Cureus
December 2024
Internal Medicine, Guthrie Lourdes Hospital, Binghamton, USA.
In narcolepsy with cataplexy, sodium oxybate and the recently FDA-approved drug pitolisant are preferred medications. Armodafinil, a longer-acting, non-amphetamine stimulant, is often used in patients who have narcolepsy without cataplexy. It enhances alertness by increasing presynaptic dopamine transmission presynaptically, amplifying serotonin in the cerebral cortex, activating glutamatergic circuits, which may contribute to its vigilance-enhancing properties, and stimulating orexin activity.
View Article and Find Full Text PDFEfficacy of oral modafinil on accelerating consciousness recovery in adult patients with moderate to severe acute traumatic brain injury admitted to intensive care unit: a randomized double-blind clinical trial.
Neurosurg Rev
December 2024
Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Chamran Blvd, Shiraz, 7194815711, Iran.
Background: Traumatic Brain Injury (TBI) is a leading cause of hospitalization and disability in young and middle-aged adults. This study aims to survey the efficacy of oral modafinil, a low-side-effect central nervous system stimulant, in the enhancement of consciousness recovery in moderate to severe TBI patients in the ICUs of a referral trauma center.
Materials And Methods: All ICU patients meeting inclusion criteria between April 2021 and April 2023 were screened.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!